Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

Summary

This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers

Timeline

Start

2023-12-28

Primary completion

2030-11

Completion

2030-11

Drugs

Indications